Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30232971 | 0.89 | MAPK1 (0.36) | MAPK1MAP4K1 | |
| SCHEMBL30232855 | 0.86 | DAO (0.33) | MAPK1 | |
| SCHEMBL21990467 | 0.85 | MAPK1 (0.34) | MAPK1 | |
| SCHEMBL21990591 | 0.79 | GRM2 (0.33) | CSF1RMAP4K1 | |
| SCHEMBL30232883 | 0.78 | MAP4K1 (0.33) | MAPK1MAP4K1 | |
| SCHEMBL22012276 | 0.76 | MAP4K1 (0.33) | CSF1RPARP1MAP4K1 | |
| SCHEMBL21990473 | 0.76 | PARP1 (0.31) | CSF1RPARP1MAP4K1 | |
| SCHEMBL30233103 | 0.76 | PIK3CD (0.34) | — | |
| SCHEMBL21990475 | 0.76 | CSF1R (0.33) | CSF1RPARP1 | |
| SCHEMBL30232834 | 0.74 | MAP4K1 (0.37) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197703-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-3880676-B1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200172539-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | MAPK1 426/4885CSF1R 450/4885PARP1 966/4885 |
| US-20200172539-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | MAPK1 444/4885CSF1R 410/4885PARP1 1047/4885 |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | MAPK1 444/4885CSF1R 410/4885PARP1 1047/4885 |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | MAPK1 426/4885CSF1R 450/4885PARP1 966/4885 |
| US-20240197703-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | MAPK1 426/4885CSF1R 450/4885PARP1 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.